Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment

Andrew R. Clamp; Iain A. McNeish; Andrew Dean; Dolores Gallardo‐Rincón; Ji‐Hoon Kim; Dearbhaile M. O’Donnell; Jane Hook; Sarah P. Blagden; James D. Brenton; Raj Naik; Timothy Perren; Sudha Sundar; Adrian Cook; Elizabeth C James; Hani Gabra; Rosemary Lord; Marcia Hall; G. Dark; Richard Kaplan; Jonathan A. Ledermann

doi:10.1093/annonc/mdy285.151

Abstract

Background: Neoadjuvant carboplatin-paclitaxel (CT) with delayed primary surgery (DPS) after 3 cycles is a standard-of-care option for women with bulky FIGO stage IIIc-IV EOC. However, radiological and biochemical response to neoadjuvant CT has not been prospectively evaluated nor compared with DPS outcome and progression-free survival (PFS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Clamp et al. (2018) studied this question.

synapsesocial.com/papers/6a7223192fdcb5703edb88cd https://doi.org/10.1093/annonc/mdy285.151

View Full Paper

Ask AI

Bookmark

Share

Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment

Abstract

Discussion

Cite This Study

Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment

Abstract

Discussion

Cite This Study

Keep reading

Keep reading